Compositions and methods for targeting solid tumors with chimeric antigen receptor (car) macrophages
AssigneeRutgers, The State University of New Jersey
InventorPingping Hou
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating cancer in a subject. In some embodiments, the compositions and methods may be used for treating solid tumor cancers. In some embodiments, the compositions and methods may comprise a modified macrophage or monocyte comprising a surface-expressed phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) polypeptide to specifically target solid tumors. The modified macrophage or monocyte comprising the surface-expressed PS-targeted CAR polypeptide may activate an immune response in a tumor microenvironment in the subject, thereby treating the cancer in the subject.
Claims23
A polynucleotide construct encoding a phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) polypeptide, the PS-targeted CAR polypeptide comprising:
- (a) a signal peptide;
- (b) an extracellular PS-binding domain;
- (c) a hinge domain;
- (d) a transmembrane domain;
- and
- (e) one or more intracellular immunostimulatory activation domains.
A modified macrophage or monocyte comprising a surface-expressed phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) polypeptide, the PS-targeted CAR polypeptide comprising:
- (a) a signal peptide;
- (b) an extracellular PS-binding domain;
- (c) a hinge domain;
- (d) a transmembrane domain;
- and
- (e) one or more intracellular immunostimulatory activation domains.
(canceled)
(canceled)
A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a modified macrophage or monocyte comprising a surface-expressed phosphatidylserine (PS)-targeted chimeric antigen receptor (CAR) polypeptide, the PS-targeted CAR polypeptide comprising:
- (a) a signal peptide;
- (b) an extracellular PS-binding domain;
- (c) a hinge domain;
- (d) a transmembrane domain;
- and
- (e) one or more intracellular immunostimulatory activation domains.
23-26. (canceled)
Dependencies are inferred from the claim text.